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Abstract
Objective: Progesterone (P4) plays a central role in women's health. Synthetic progestins are used clinically in
hormone replacement therapy (HRT), oral contraceptives, and for the treatment of endometriosis and infertility.
Unfortunately, synthetic progestins are associated with side effects, including cardiovascular disease and breast
cancer. Botanical dietary supplements are widely consumed for the alleviation of a variety of gynecological issues,
but very few studies have characterized natural compounds in terms of their ability to bind to and activate
progesterone receptors (PR). Kaempferol is a flavonoid that functions as a non-steroidal selective progesterone
receptor modulator (SPRM) in vitro. This study investigated the molecular and physiological effects of kaempferol in
the ovariectomized rat uteri.
Methods: Since genistein is a phytoestrogen that was previously demonstrated to increase uterine weight and
proliferation, the ability of kaempferol to block genistein action in the uterus was investigated. Analyses of
proliferation, steroid receptor expression, and induction of well-established PR-regulated targets Areg and Hand2
were completed using histological analysis and qPCR gene induction experiments. In addition, kaempferol in silico
binding analysis was completed for PR. The activation of estrogen and androgen receptor signalling was determined
in vitro.
Results: Molecular docking analysis confirmed that kaempferol adopts poses that are consistent with occupying
the ligand-binding pocket of PRA. Kaempferol induced expression of PR regulated transcriptional targets in the
ovariectomized rat uteri, including Hand2 and Areg. Consistent with progesterone-like activity, kaempferol
attenuated genistein-induced uterine luminal epithelial proliferation without increasing uterine weight. Kaempferol
signalled without down regulating PR expression in vitro and in vivo and without activating estrogen and androgen
receptors.
Conclusion: Taken together, these data suggest that kaempferol is a unique natural PR modulator that activates
PR signaling in vitro and in vivo without triggering PR degradation.
Keywords: Kaempferol; Progestin; Progesterone receptor; Genistein;
Hormone replacement therapy; Botanicals
Introduction
Progesterone (P4) plays an essential role in female health. The
importance of P4 has led to the continued development of synthetic
progesterone receptor (PR) ligands for a variety of women’s health
issues [1,2]. For example, oral contraceptives, combination hormone
replacement therapy (HRT) for the treatment of menopausal
symptoms, and to reduce the risk of endometrial hyperplasia and
cancer associated with unopposed E2 therapy [3-5]. These common
treatments contain synthetic progestins, such as medroxyprogesterone
acetate (MPA), which are associated with deleterious side effects
including cardiovascular disease, heart attack, stroke, and breast
cancer [6,7]. Side effects are thought to occur primarily due to the
promiscuous binding of synthetic progestins to other nuclear
receptors such as the androgen receptor (AR), glucocorticoid receptor
(GR), and mineralocorticoid receptor (MR) [8]. Therefore, the
identification of progestins that have tissue and receptor specificity
with minimal side effects is important.
Due to the side effects associated with HRT and the perceived safety
of natural remedies, millions of menopausal women are seeking
alternative therapies in the form of botanical extracts and dietary
supplements [9]. Most of the formulas used to treat menopausal
symptoms contain estrogenic compounds, such as genistein and 8-
prenyl-naringenin that bind and activate estrogen receptors.
Unopposed estrogen signaling in the uterus is associated with
hyperplasia and cancer [10]. P4 when combined with E2 protects
against proliferation and hyperplasia of endometrial cells [11].
Therefore, botanical formulations containing both a phytoestrogen
and a phytoprogestin should be safer in the uterus. Some botanicals
have been identified that contain progestogenic compounds as
demonstrated by in vitro and in vivo assays [12-17].
Selective PR modulators (SPRMs) are a class of PR ligands that
function as an agonist, antagonist, or mixed agonist/antagonist and
have clinically relevant tissue selectivity [4]. Previous studies
demonstrated kaempferol is a non-steroidal phytoprogestin that
functions in a cell-specific manner in vitro [13]. Kaempferol is a
widely distributed dietary flavonoid found in fruits and vegetables that
also has anti-oxidant and anti-inflammatory properties [18]. The anti-
inflammatory properties of kaempferol appear to be meditated by
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nuclear factor-κB (NFκB) [19,20]. In animal studies, kaempferol
inhibited ovarian cancer tumorigenesis and angiogenesis [21,22].
Moreover, in human epidemiological studies, kaempferol intake
significantly decreased (40%) ovarian cancer incidence [21]. The
biological activities demonstrated by kaempferol in these previous
studies are consistent with kaempferol functioning as a progestin,
especially considering progestins are known to inhibit NFκB and are
well known to protect against ovarian cancer [23-25].
The objective of this study was to investigate if kaempferol exerts
progesterone-like effects in vivo using the ovariectomized Sprague-
Dawley rat model. Since genistein is a phytoestrogen that was
previously demonstrated to increase uterine weight and proliferation
[3], the ability of kaempferol to block genistein action in the uterus
was investigated. Analyses of proliferation, steroid receptor expression,
and induction of well-established PR-regulated targets Areg and
Hand2 were completed. In addition, kaempferol in silico binding
analysis was completed for PR, as was the activation of ER and AR
signaling in vitro in order to determine receptor specificity. The data
from this study suggest that kaempferol interacts with PR, activates the
receptor without stimulating its degradation, antagonizes genistein-




All chemicals and reagents were purchased from Fisher (Hanover
Park, IL) or Sigma-Aldrich (St. Louis, MO) unless otherwise indicated.
All media for cell culture were purchased from Life Technologies, Inc
(Carlsbad, CA). Fetal bovine serum (FBS) and charcoal stripped serum
was purchased from Atlanta Biologicals (Norcross, GA). Genistein and
kaempferol were purchased form Indofine Chemical Co. (Belle Mead,
NJ) and Sigma-Aldrich (St. Louis, MO). Desmethylarzoxifen (DMA)
was provided by Dr. Gregory Thatcher (Department of Medicinal
Chemistry, University of Illinois at Chicago).
Molecular modeling
The crystal structure of the human PR in complex with the agonist
P4 (PDB: 1A28; 1.8 Å) was used in the docking procedure [26]. The
protein model was analyzed using the protein structure preparation
module in MOE [27]. All ligands and water molecules were removed
and hydrogen atoms were added using Protonate3D. This structure
was saved as a PDB file. The 3D structures of the ligands were built
and inspected with VIDA and AM1-BCC [28] partial atomic charges
were calculated with Molcharge [27] and minimized using OMEGA
[27]. All ligands were docked into the binding pocket of PR using
GOLD (version 5.1, CCDC, Cambridge, UK) [29]. The active site was
defined as all protein atoms within 6 Å of P4. The scoring function
used to rank the docked poses was Chem-PLP. A maximum of twenty
docking solutions were generated for each structure, with early
termination of the process if the respective RMSDs of the three highest
ranked docking solutions were within 1.5 Å RMSD of one another
(GOLD default 1 setting: 100,000 Genetic Algorithm (GA) Operations,
5 islands). Flipping of ring free corners, amide bonds, protonated
carboxylic acids and planar or pyramidal nitrogen atoms were allowed.
MOE was also used to analyze the docking results and generate figures.
The top-ranked poses were further co-minimized using MOE LigX
module utilizing AMBER12HT force field for optimization and
calculation of affinity score [30].
Cell culture and cell lines
Human endometrial stromal cells (HESCs) were provided by Dr.
Asgerally Fazleabas (Department of Obstetrics, Gynecology, and
Reproductive Biology, Michigan State University, Grand Rapids, MI).
HESCs were cultured according to a previous study [29].
Luciferase assay
HESCs were grown in 12-well plates until 80% confluent. MDA-231
were grown in 12-well plates at 100,000 cells per well. Progesterone
responsive element (PRE), estrogen responsive element (ERE), or
prostate specific antigen (PSA) was performed as previously described
and the transfection efficiency and cell viability was normalized to a
co-transfected beta-galactosidase plasmid (β-gal) [13]. Transfections
preceded treatment for 24 or 48 hours. Cell lysates (50 μL) were placed
in 96-well plate. The luciferase activity was quantified as previously
described [29]. The results are presented as the average fold induction
of treated over untreated cells (DMSO) after correcting for
transfection efficiency from triplicate experiments.
Western Blot Analysis
HESC cells were incubated in serum free media with various agents
for 48 hours. Cells were lysed in 1X RIPA buffer (50 mM Tris, pH 7.6,
150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (w/v) SDS) and Roche
protease inhibitor (Roche, Madison, WI). Protein concentrations were
measured using BCA protein assay reagent (BioRad, Hercules, CA).
Protein was separated by 7% SDS-PAGE and transferred onto
nitrocellulose membrane. Membranes were blocked in 5% non-fat
milk in Tris-buffered saline-Tween (TBS-T-1%). PR-A/B proteins
were probed for with antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) in 5% milk in TBS-T. Membranes were re-probed for actin (Cell
Signaling, Danvers, MA) as loading control. Signals were detected
using chemiluminescence SuperSignal West Femto Chemiluminescent
Kit, (Thermo Scientific, Hanover Park, IL) according to the
manufacturer’s protocol on Protein Simple FluorChem E (Santa Clara,
CA).
Rat study
All animal studies were approved by the UIC Animal Care and Use
Committee. Sprague-Dawley ovariectomized (OVX) rats were utilized
for this study to eliminate endogenous hormone production. Twenty-
four animals weighing 160-180 g were purchased for the study (n=8/
group) (Harlan Laboratories, Madison, WI). All rats were housed at
21°C in 12 h light:12 h dark cycles and were fed 7% corn diet (Harlan
Laboratories, Madison, WI) devoid of phytoestrogens. Two weeks post
ovariectomy, 5.625 mg kaempferol or genistein was dissolved in a
DMSO/corn oil mixture and given via oral gavage daily for 8 days
based on a previous study demonstrating estrogenic action of genistein
at this dose and duration [3]. Control animals were given DMSO/corn
oil only. Animals were sacrificed 24 h after the last injection.
Immunohistochemistry
Uteri were carefully excised, weighed, and fixed in 4%
paraformaldehyde overnight. Histological analyses were performed
according to a previously published study [31]. Primary antibodies
utilized in this study included Ki67 (Abcam, Cambridge, MA), PR,
ERα and Hand2 (Santa Cruz Biotechnology, Santa Cruz, CA) [32]. For
PR, ERα and Ki67, a biotinylated horseradish peroxidase-conjugated
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anti-rabbit IgG was used as the secondary antibody (1:200, Vector,
Burlingame, CA). For Hand2 detection a biotinylated horseradish
peroxidase-conjugated anti-goat IgG was used as the secondary
antibody (1:200, Vector, Burlingame, CA). Secondary antibody
incubation was followed by ABC peroxidase detection enhancement
(Vector, Burlingame, CA) and detected by DAB as the chromogen
(Vector, Burlingame, CA). Slides were counterstained with
haemotoxylin and photomicrographs of sections were obtained using
Nikon Eclipse E600 microscope. To assess proliferation in the luminal
epithelial cells, a minimum of 300 cells were quantified (2 sections per
animal) and the average taken. Data are represented as percentage of
positive cells. In the stroma, the entire endometrial section was
examined, and the number of proliferating stromal cells was
categorized as 0, no staining; fewer than 5, low; and more than 5, high.
High, low and absent Ki67 expression was classified in endometrial
stroma for all four groups.
qPCR
Uterine RNA was isolated using Trizol (Invitrogen, Carlsbad, CA)
reagent as per manufacturer’s instructions. The quality of total RNA
was determined spectrophotometrically. Complementary DNA was
made using RevertAid first strand cDNA synthesis kit (Fermentes,
Glen Burnie, MD) in a total volume of 20 μl. Each real-time PCR
consisted of 100 ng cDNA, 10 μl FastStart SYBR Green PCR Master
Mix (Roche, Madison, WI), and 0.5 μM forward and reverse primers
(IDT, San Jose, CA). PCR analyses were conducted using the following
set of primers; Gapdh 5’- CATGGCCTTCCGTGTTCCTA-3’
(forward) and 5’-CCTGCTTCACCACCTTCTTGAT-3’ (reverse),
Rpl1 5’- CTGTGAGGGCATCAACATTTC-3’ (forward) and 5’-
GTTGGTGTTCATCCGCTTTC-3’ (reverse), ERα 5′-
AATTCTGACAATCGACGCCAG-3’ (forward) and 5’-
GTGCTTCAACATTCTCCCTCCTC-3’ (reverse), PR 5’-
CCCGACACTTCCAGCTCTTT-3’ (forward) and 5’-
TGTGGGATTTGCCACATGGT-3’ (reverse), Hand2 5’-
AAGAGGAAGAAAGAGCTGAATGAGAT-3’ (forward) and 5’-
CGTTGCTGCTCACTGTGCTT-3’ (reverse), Areg 5’-
AACTGAACTTCTGGAGCCTTC-3’ (forward) and 5’-
CATGCCATAGCCTAGCTGAT-3’ (reverse). Fold change in mRNA
expression was determined via the ΔΔCt method, with Gapdh as an
internal control for Areg and Rlp1 for Hand2, PR and ERα. Data
reported are the mean fold change ± SEM for three replicates
compared to vehicle control.
Statistical analysis
All data were analyzed using one-way ANOVA, followed by
Tukey’s test for multiple comparisons. Statistical significance was
defined as #p < 0.05 between groups, *p < 0.05 compared to control,
groups not marked were not statistically different from each other.
Results
Molecular modeling of kaempferol, MPA and P4 in PRLigand Binding Domain (LBD)
Kaempferol was previously reported to bind to PR, activate PRE-
luciferase in a concentration-dependent manner, and it was
antagonized by RU486 in T47D and human endometrial stromal cells
(HESC) [13]. In order to further characterize the ability of kaempferol
to bind the PR, a molecular docking study was used to highlight and
compare the binding interactions of kaempferol with those of RU486,
P4, and MPA at active site residues. Kaempferol fits into the ligand
binding domain (LBD) and has an affinity score comparable to those
of RU486, P4, and MPA (Table 1). Consistent with previous reports,
RU486 is a stronger PR binder as compared to P4 and demonstrated
the highest affinity score [33]. Top poses of MPA and kaempferol are
shown in Figure 1. The 4’-, 5-, and 7-hydroxyl groups of kaempferol
form hydrogen bonds with Gln725, Thr894, Asn719, respectively. The
binding pose of MPA is very similar to P4 and RU486. In addition to
the hydrogen bond between the 3-keto group and the side chain amide
moiety of Gln725, the acetate group in kaempferol extends into the
pocket formed by Leu715, Leu718 and Phe794, which is occupied by
the 17α-propynyl group in RU486. Kaempferol’s interaction with the
LBD of PR is driven by a combination of hydrogen bonding and






Table 1: Known progesterone receptor ligands used in this study and
affinity scores for the best docking poses after co-minimization in the
binding site
Figure 1: Kaempferol (cyan) and MPA (magenta) bound to the
ligand binding domain of PR.
The interactions of the aromatic rings of kaempferol and MPA are
similar to P4 in the ligand binding domain of the receptor. The 4’-
hydroxyl group of kaempferol anchors to Gln725 analogous to the
keto group of P4 or MPA. Additionally, the 7-hydroxyl moiety on the
phenyl ring forms a hydrogen bond with Asn719 and the 5-hydroxyl
group interacts with Thr894. MPA gains more interactions through its
ester linked arm that extends into the cavity formed by Leu715,
Leu718 and Phe794.
Kaempferol does not increase uterine weight of OVX rats
Since botanicals are mixtures and are often consumed as multi-
botanical formulations, the ability of kaempferol to oppose genistein
action in the uterus was investigated [34-36]. Genistein is a
phytoestrogen found in commonly used botanical supplements soy
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and red clover that activates ER and increases uterine weight and cell
proliferation similar to E2 [3]. Based on a previous study, Sprague-
Dawley rats (200 g) fed 375 μg genistein/g of food/day demonstrated
significant uterine weight gain and proliferation [3].
The dose of genistein and the length of treatment in this study were
calculated based on the average amount of food consumed per day (15
g/animal/day), indicating that genistein at 5.625 mg/animal/day for 8
days should significantly induce uterine proliferation. Kaempferol’s
ability to block genistein-induced proliferation in OVX rats after 8
days of oral treatment was investigated (Table 2). As expected, the
uterine wet weights of genistein-treated animals were significantly
higher than control rats (Table 2). Oral administration of an equal
dose of kaempferol (5.625 mg/animal/day) did not significantly
increase uterine wet weight compared to control group, indicating that
kaempferol did not induce an estrogenic response in the uterus (Table
2), consistent with previous reports [37,38]. Additive effects were not
observed on uterine weight in animals co-treated with kaempferol and
genistein.
Treatment (5.625mg/animal/day) Uterine Weight (mg)
Vehicle (control) 63.3 ± 24
Genistein 90.0 ± 17*
Kaempferol 52.0 ± 25
Genistein + Kaempferol 95.7 ± 22*
Table 2: Genistein induced uterine wet weight increase in OVX
Sprague-Dawley rats. Animals were administered with vehicle control,
genistein, kaempferol and geninstein+kaempferol for 8 days via oral
gavage. Data are uterine wet weights (mg) 24 h after last treatment (n
= 8 per group). Mean ± SEM (∗p < 0.05) as determined by one-way
ANOVA test.
Kaempferol inhibits uterine epithelial cell proliferation
P4 opposes ER-mediated proliferation in the uterine luminal
epithelium, while also preparing the uterine stroma to respond to E2
by inducing stromal proliferation [39-41]. Therefore, the effect of
kaempferol, genistein, and the combination on proliferation of rat
uterine epithelial cells was investigated. Ki67 staining was utilized to
quantify proliferation. Genistein significantly increased luminal
epithelial proliferation as compared to control (Figure 2A).
These results are in agreement with previously conducted studies
[14]. Kaempferol alone did not increase luminal epithelial
proliferation. Importantly, kaempferol when given in combination
with genistein decreased proliferation of the uterine luminal epithelial
as compared to genistein alone (Figure 2A and 2B). Due to minimal
proliferation in the stroma, a semi-quantitative assessment method
was used to investigate Ki67 expression. Co-administration of
kaempferol and genistein stimulated proliferation of uterine stromal
cells when compared to the individual treatments and vehicle control
(Figure 2C). These changes in luminal and stromal proliferation from
co-administration of kaempferol and genistein are consistent with
similar studies which assessed actions of P4 in the presence of E2
[11,42].
Figure 2: Cell proliferation in response to oral treatment with
vehicle (control), genistein, kaempferol and genistein+kaempferol
in OVX rat uteri. Representative sections of uterus immunostained
for Ki67 (A). Results are represented as percentage of Ki67 positive
cells in the luminal epithelium (B). In the stroma, Ki67 staining was
categorized as low, medium or high, and shown as percentage of
animals from each category (C). Data represented as mean ± SEM
of Ki67 positive cells (n = 4 per group). ∗p < 0.05, significantly
different from control, #p < 0.05, significantly different between
groups. Scale bar=100 μm.
Kaempferol induces Areg mRNA expression and Hand2
protein levels in the uterus
The anti-proliferative action of P4 in the uterine epithelial cells is
mediated by Hand2 induction [4,32]. Immunohistochemistry and
qPCR analyses were used to investigate if Hand2 induction correlated
with the anti-proliferative effects of kaempferol.
As predicted, an increase in Hand2 expression was observed in
uterine stromal cells after kaempferol treatment (Figure 3A). Hand2
protein expression was not induced by genistein, and a slight increase
was observed in rats treated with both genistein and kaempferol
(Figure 3A). Hand2 mRNA changes were not observed in any of the
treated animals (Figure 3B). The observed discrepancy between Hand2
protein and mRNA expression is likely based on the technique, as
immunohistochemistry allows for analysis of specific uterine cell types,
whereas the mRNA analyzed was a heterogeneous mixture of all
uterine cell types.
Amphiregulin (Areg) is a secreted protein that is induced by P4 in
the uterus [43]. Kaempferol treatment significantly induced (5-fold)
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Areg mRNA compared to vehicle treated animals, suggesting that it
can function to increase PR-regulated targets in vivo (Figure 3C).
Genistein blocked kaempferol-induced Areg expression, consistent
with the antagonistic effects of E2 on P4-mediated induction of Areg
[43]. Since Areg is a secreted protein, it was not investigated via
immunohistochemistry [43].
Figure 3: Immunohistochemistry and mRNA expression of P4
targets (Hand2 and Areg) in the rat uterus after treatment with
vehicle control, genistein, kaempferol, and genistein+kaempferol
for 8 days. Kaempferol induced expression of Hand2 protein (A)
but not mRNA (B), and induced Areg mRNA (C) in the
ovariectomized rat uterus. Arrows indicate the uterine stromal
compartment. Bar=100μm. qPCR analyses were performed using
SYBR technologies. Results were normalized to Rpl1 for Hand2 or
Gapdh for Areg. Mean ± SEM, ∗p < 0.05, significantly different
from control, #p < 0.05, significantly different between groups.
Scale bar=100 μm.
Genistein and kaempferol treatment modulated uterine PR
and ERα protein and mRNA expression
Steroid receptor mRNA and protein levels can be influenced by
several physiological factors, including exposure to E2 and P4 [44]. To
investigate the effects of genistein and kaempferol on steroid receptor
expression in the uterus (the myometrium, endometrial stroma,
luminal and glandular epithelium), mRNA levels of ER and PRA were
measured. To establish cell type specific PR and ER regulation of
steroid receptor expression, protein levels were compared using
immunohistochemistry.
ERα bound to E2 triggers its proteasome-dependent protein
degradation [4,45]. In order to study ERα regulation, first qPCR for
the receptor was performed. ERα mRNA levels in whole uterus were
not affected by genistein treatment, but was significantly induced by
kaempferol and kaempferol combined with genistein (Figure 4A). To
investigate ERα protein expression in the different uterine cell types,
immunohistochemical analyses were performed. As expected,
genistein downregulated ERα protein expression (Figure 4B).
Figure 4: Immunohistochemistry and mRNA expression of ERα
and PR in the rat uterus after treatment with vehicle control,
genistein, kaempferol, and genistein+kaempferol for 8 days.
Kaempferol and genistein differentially regulate PR and ERα
mRNA, protein expression, and localization in the uterus. qPCR
analyses were performed using SYBR technologies (A) and uterine
sections were stained for ERα (B) and PR (C) expression, n=8 per
group. Bar=100 μm. All results were normalized to RPL1. Mean ±
SEM. ∗p < 0.05, significantly different from control. Groups
unmarked were not statistically different from each other.
Interestingly, the induction of ERα mRNA in animals treated with
kaempferol alone and in combination group (genistein and
kaempferol) was significant and paralleled protein levels (Figure 4A).
The lack of uterine weight gain and ERα expression in kaempferol-
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treated rats confirmed that kaempferol did not function as an
estrogenic compound.
PR is an ER-regulated target [44]. Genistein treatment significantly
increased PR mRNA and protein expression, confirming that genistein
acts as a phytoestrogen in rat uteri [46]. Interestingly, kaempferol and
kaempferol combined with genistein also significantly upregulated PR
mRNA (Figure 4A). PR immunostaining in the vehicle-treated rat
uteri was intense and localized to the nucleus throughout the luminal
and glandular epithelial cells, but exposure to genistein and
kaempferol increased PR expression in the stroma (Figure 4C).
Therefore, kaempferol blocked genistein-induced proliferation and
induced expression of PR target genes (Areg mRNA and Hand2),
which is consistent with kaempferol functioning as a progestin.
However, kaempferol acted without stimulating the degradation and
loss of PR protein or mRNA expression, which typically occurs when
PR binds a ligand (Figure 4C).
Kaempferol, E2 and genistein regulation of PR expression inhuman endometrial stromal cells (HESC)
Upon P4 binding, PR is targeted for proteasomal degradation,
which could be partially responsible for the resistance to progestin
therapy observed in endometriotic patients consuming progestins
chronically [47].
Figure 5: Regulation of PR protein expression in human
endometrial stromal cells. Cells were incubated with pure
compound for 48 hours. PRA and PRB were induced by E2 (1 μM),
genistein (5 μM) and kaempferol (20 μM) as determined by
densitometry (A). PR fold change was analyzed using Image-J in
triplicate experiments. *p < 0.05, indicates significant fold change of
PR compared to basal DMSO. MPA (20 μM) did not induce PRA
and PRB. Membranes were blotted for actin as a loading control
(B). Image is a representative blot, experiment repeated in
triplicate.
Increased PR expression is mediated by the interaction between
ligand-occupied ER with ERE in the PR gene promoter [44]. Since PR
mRNA and protein was not reduced in the uteri of kaempferol-
stimulated rats and instead actually increased, the regulation of the PR
was investigated in vitro. PRA and PRB protein expression was
analyzed in HESCs treated with MPA, P4, kaempferol, E2, and
genistein (Figure 5). As expected, after a 48-hr treatment with MPA,
HESCs had reduced PR protein expression (Figure 5A). HESCs
exposed to E2 or genistein had increased PR protein expression (Figure
5B). The combination treatment of MPA and E2 maintained PR
expression at basal levels. Similar to the in vivo results in rat uteri,
kaempferol increased PR protein expression (Figure 5A and 5B).
When combined with genistein treatment, kaempferol decreased
genistein-induced PR expression, similar to MPA when combined
with E2.
Kaempferol does not induce ERE-luciferase in HESCs
Enhanced PR protein expression in the uterine stroma from
kaempferol treatment in vivo could be due to activation of ER, which
in turn transcriptionally induces PR [44]. Although kaempferol was
previously reported to function as an ER modulator in HeLa cells, rat
primary osteoblasts and human breast cancer MCF-7 cells in a
concentration range of 10-70 μM [48-52], the ability of kaempferol to
activate the ER in HESCs has not been reported. Therefore, HESCs
were treated with a vehicle control, genistein, kaempferol, and
genistein combined with kaempferol and ER activation was monitored
by ERE-luciferase transcription (Figure 6). E2 and genistein, but not
kaempferol significantly induced ERE-luciferase expression in HESCs
(Figure 6). In agreement with PR protein expression (Figure 5),
genistein (5 μM) was as active as E2 at inducing ERE-luciferase
transcription (Figure 6). The ER antagonist desmethylarzoxifen
(DMA) (100 nM) significantly inhibited E2-induced signaling
suggesting that these activities are mediated through ER. Despite
increased PR protein expression after kaempferol treatment, ERE
transcription was not significantly activated (Figure 6).
Figure 6: ERE-luciferase induction in human endometrial stromal
cells. Endometrial stromal cells were transiently transfected with
ERE-luciferase and ERα and treated with pure compounds E2 (1
μM), genistein (5 μM), and kaempferol (20 μM) with and without
the ER antagonist DMA (100 nM) for 48 hours. Data represent
mean fold change ± SEM of relative light units normalized to β-gal
in triplicate experiments. (a) indicates significant luciferase
induction compared to basal DMSO; (b) indicates significant
reduction of luciferase induction by DMA as determined by
Student’s t-Test, n=3, *p < 0.05.
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Kaempferol does not induce PSA-luciferase in MDA-MB-231
cells
MPA is one of the most commonly used synthetic progestins [8,53].
Although MPA signals through PR, it also activates other nuclear
receptors such as AR, thereby increasing side effects and the risk of
breast cancer and cardiovascular disorders [8,54,55]. Thus, it was
important to evaluate if kaempferol also activates AR signaling. As
PRE and ARE have similar consensus sequences, it is difficult to
accurately determine androgen-specific activity when both PR and AR
are expressed in a cell [34,56]. Therefore, in this experiment, MDA-
MB-231 breast cancer cells, which express AR but not PR, were used.
Prostate specific antigen (PSA) is an AR-regulated gene and its
proximal promoter is highly responsive to androgens [56,57]. Thus,
PSA-luciferase activity was measured in MDA-MB-231 cells to
monitor AR activation. As expected, MPA activated PSA-luciferase in
MDA-MB-231 cells, verifying that MPA stimulates AR-mediated
transcription (Figure 7). In the presence of RU486 (1 μM), an AR
antagonist, MPA-induced AR signaling was completely inhibited,
further demonstrating MPA activation of AR-mediated transcription
(Figure 7). Although there was a trend for increased activation with
kaempferol, this was not statistically significant.
Figure 7: PSA-luciferase induction in MDA-MB-231 cells. MDA-
MB-231 cells were transiently transfected with PSA-luciferase and
treated with pure compounds kaempferol (20 μM), P4 (1 μM), and
MPA (1 μM)) with and without AR antagonist RU486 (1 μM) for
48 hours. MPA activates PSA-luciferase and can be antagonized by
RU486. Kaempferol and P4 did not significantly activate AR
signaling. Data represent mean fold change ± SEM of relative light
units normalized to β-gal in triplicate experiments. (a) indicates
significant luciferase induction compared to basal DMSO; (b)
indicates significant reduction of luciferase induction by RU486 as
determined by Student’s t-Test, *p < 0.05.
Discussion
Many studies have provided evidence that kaempferol may function
as progestin, including (i) activation of PR signaling in vitro [13], (ii)
antagonistic effects when a potent PR agonist is present [13], (iii)
similar anti-inflammatory mechanisms when compared to P4 [18,20]
and (iv) protection against ovarian cancer [22,58,59]. To date, there
are no reports regarding the progestogenic effects of kaempferol in
vivo. Therefore, this study investigated the effects of kaempferol on P4
signaling in the uteri of OVX Sprague-Dawley rats and steroid
receptor activation in vitro. In this study, the kaempferol treatment of
cultured cells and animals were within the range used in previous
studies (10-70 µM and 1-100 mg/kg, respectively) [3,13,18,60,61].
These findings, together with previous data, collectively suggest that
kaempferol may have the potential to provide progestogenic biological
activity in vivo, particularly in the uterus.
Computational analysis demonstrated that kaempferol adopts
binding poses, which closely mimic the binding conformation and the
interactions commonly observed between the LBD of PR and
established ligands. The hydrophobic and hydrogen bond interactions
of kaempferol are highly analogous to those of the steroid scaffold of
P4. In addition to the interactions expected for the steroid-based
backbone of MPA, it gains additional interactions with the binding site
through its ester-linked appendage, which may be associated with its
agonistic effects. Molecular modeling data are consistent with previous
in vitro binding analysis performed with kaempferol and the PR ligand
binding domain [13]. Future investigations using additional molecular
modeling techniques to study the recruitment of coregulatory proteins
are warranted to elucidate the molecular mechanisms of kaempferol as
a selective progesterone receptor modulator.
One well-established function of P4 is the inhibition of E2-induced
uterine cell proliferation [1,11]. As a result, progestins are used
therapeutically to reduce the proliferation of E2-dependent
endometrial cancers and in endometriosis [62]. Kaempferol reduced
genistein-induced proliferation in luminal epithelial cells, while
preparing the uterine stroma to respond to genistein, leading to
stromal cell proliferation. Hand2 mediates the anti-proliferative effects
of P4 in the uterus [32]. Although kaempferol treatment stimulated
Hand2 protein expression in the uterine stroma, there was no change
in Hand2 mRNA expression. Hand2 mRNA and protein expression in
kaempferol treated uteri likely do not correlate completely because
Hand2 is expressed in a discrete area within the uterine stroma, easily
detectable by immunohistochemistry, but constituting only a small
portion of the total uterine mRNA. Previous in vivo studies have
reported that P4 treatment completely abolished E2-induced
proliferation in the uterine epithelium [39,40]. Although kaempferol
significantly reduced genistein-mediated proliferation in the uterus, it
did not completely eliminate proliferation. However, it is important to
note that the differences between P4 and kaempferol could be due to
different routes of treatment administration (oral vs. subcutaneous),
potency, and duration. P4 is poorly orally bioavailable driving the
administration of synthetic progestins, like MPA. Since genistein and
kaempferol are biologically active in the uterus after oral
administration, botanicals (or combination therapies) containing both
estrogenic and progestogenic compounds might provide the desired
benefits for mitigating menopausal symptoms while also preventing
E2-induced uterine hyperplasia.
Reduced PR protein following progestin administration occurs in
P4 responsive cell types, and may be used to study progestogenic
action within a target tissue [13,63,64]. Unexpectedly, the uteri of
kaempferol-treated rats maintained expression of PR in vivo and in
HESCs. This finding was especially intriguing because PR induction is
linked to estrogenic signaling [32,35,66], which was not observed with
kaempferol treatment, in vitro or in vivo as demonstrated by no
change in ERE-luciferase expression and a lack of increased uterine
weight. While kaempferol has been described as a partial ER agonist in
human breast cancer cells and cervical cells [49,50], multiple studies
investigating the estrogenic actions of kaempferol in vivo detected no
uterotrophic estrogenic effects [37,60], which is further corroborated
in this study. Progestin therapy resistance occurs in some populations
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of patients with endometrial cancer and endometriosis due to reduced
or loss of PR protein expression after prolonged treatment [51,67,68].
Endometrial cancer is the most common gynecological malignancy in
the United States and the fifth most common cancer among women in
the world [47,53,69]. The anti-proliferative effects of kaempferol,
without simultaneously downregulating PR expression raises an
interesting possibility that a novel therapeutic approach could be
attempted using kaempferol as an alternative for longer-term
management of endometriotic symptoms.
The mechanism of progestin action is complex and may exert
effects other than those traditionally expected from progestogenic
activity [47,70]. Progestins currently available for prescription, such as
MPA, interact with other steroidal receptors, including the AR,
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR)
[8,71]. It has been proposed that AR, GR and MR activity enhance the
proliferation of mammary epithelial cells, increasing breast cancer risk
[8,72,73]. The androgenic nature of MPA has been suggested to be one
mechanism through which it may give rise to blot clots, heart attacks
and hypertension [6]. Therefore, an ideal progestin would be devoid of
non-specific GR, MR, and AR activity [8,53,74]. Contrary to MPA,
kaempferol did not significantly activate AR in vitro. However, further
studies are needed to confirm kaempferol’s action on GR and MR.
Taken together, the results from this study demonstrate that
kaempferol functions as a progestin in vivo to mediate anti-
proliferative effects of genistein in the uterus and modulate steroid
receptor expression, without activating AR and ER signaling. The
notion that phytoprogestins can be identified provides a new type of
endocrine modulator, which could interact with and change endocrine
signaling. Endocrine disruption is a critical issue as women are already
consuming botanical-based therapies for a variety of conditions, such
as infertility, menopause, and premenstrual symptoms [9,75].
Identification and characterization of progesterone-like molecules
from natural sources might allow for informed decisions regarding
their use as part of complicated multi-botanical formulations or as an
alternative to current progestin therapies.
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